France’s role in the Unified Patent Court remains unclear, especially in light of the recent revelations regarding the United Kingdom coming back into the fold, but despite this it continues to be viewed as an attractive spot – especially for pharmaceutical multinationals looking to assert their rights on the European...

Read more

France’s role in the Unified Patent Court remains unclear, especially in light of the recent revelations regarding the United Kingdom coming back into the fold, but despite this it continues to be viewed as an attractive spot – especially for pharmaceutical multinationals looking to assert their rights on the European and international stage. Supplementary protection certificate (SPC) nullity actions continue to be rife – and although they have been slow to show their effects, thanks to the COVID-19 pandemic, the reforms introduced through Macron’s Action Plan for Business Growth and Transformation appear to have changed the state of patent prosecution in France for good.

Show less